Background-Currently, the relationship between circulating lipids and abdominal aortic aneurysm (AAA) is unclear. We conducted a lipidomic analysis to identify serum lipids associated with AAA presence. Secondary analyses assessed the ability of models incorporating lipidomic features to improve stratification of patient groups with and without AAA beyond traditional risk factors. Methods and Results-Serum lipids were profiled via liquid chromatography tandem mass spectrometry analysis of serum from 161 patients with AAA and 168 controls with peripheral artery disease. Binary logistic regression was used to identify AAA-associated lipids. Classification models were created based on a combination of (1) traditional risk factors only or (2) lipidomic features and traditional risk factors. Model performance was assessed using receiver operator characteristic curves. Three diacylglycerols and 7 triacylglycerols were associated with AAA. Combining lipidomic features with traditional risk factors significantly improved stratification of AAA and peripheral artery disease groups when compared with traditional risk factors alone (mean area under the receiver operator characteristic curve [95% confidence interval], 0.760 [0.756-0.763] and 0.719 [0.716-0.723], respectively; P<0.05). Conclusions-A group of linoleic acid containing triacylglycerols and diacylglycerols were significantly associated with AAA presence. Inclusion of lipidomic features in multivariate analyses significantly improved prediction of AAA presence when compared with traditional risk factors alone. (Circ Cardiovasc Genet. 2014;7:71-79.)
A bdominal aortic aneurysm (AAA) affects ≈5% of men and ≈1% women aged >65 years and is an important cause of mortality in the elderly through aortic rupture and associated cardiovascular events. 1 Ultrasound screening programs have been shown to reduce mortality due to AAA rupture in some randomized trials. AAA screening has been introduced in some countries although AAA prevalence is lower than anticipated, questioning the feasibility of this approach. 2, 3 Identifying circulating markers for AAA has been proposed as a means to streamline screening programmes. Furthermore, discovery of AAA biomarkers could improve understanding of AAA pathogenesis, potentially highlighting novel targets for drug therapies. Relevant AAA drug targets are urgently needed because AAA pathogenesis is thought to be distinct from that of atherothrombosis. Medications effective in managing atherosclerosis cannot be assumed to limit AAA growth. 4, 5 
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Important risk factors for AAA include advanced age, male sex, smoking, and a family history of aneurysm disease. 1 The importance of dyslipidemia in AAA is less clear, and most studies investigating this have been limited to assessments of total cholesterol, triglyceride, high-density lipoprotein-cholesterol (HDL-C), and low-density lipoprotein-cholesterol (LDL-C). [6] [7] [8] [9] [10] A weakness of this approach is that these fractions incorporate multiple lipids from distinct functional groups, and subtle changes in their composition could go undetected. The development of sensitive mass spectrometry (MS)-based techniques permits comparative analyses of individual lipid species. 11 Encouraging data suggest that lipidomic profiling has the potential to identify clinically relevant markers of cardiovascular disease. Meikle et al 12 demonstrated that unstable coronary artery disease was associated with a distinct plasma lipidome. This study identified a panel of 18 lipid species which, when incorporated into a model alongside conventional atherothrombotic risk factors (including high-sensitivity C-reactive protein [CRP] ), significantly improved the ability to stratify stable and unstable patients with coronary artery disease when compared with consideration of conventional risk factors alone. To our knowledge, no studies have been conducted to characterize the serum lipidome specifically in patients with AAA, and the potential of identified lipid species to act as markers or therapeutic targets for AAA is unknown. Accordingly, we conducted a lipidomic experiment to characterize the circulating lipid profile of patients with AAA. Serum samples from 161 patients with AAA and 168 controls with peripheral artery disease (PAD) were assessed to identify AAA-associated lipid species. We constructed models incorporating lipid species and traditional cardiovascular risk factors to assess whether serum lipidome characteristics were predictive of AAA presence.
Materials and Methods

Study Design
Database searches revealed 161 patients with AAA and 168 controls with PAD eligible for inclusion in the current study. The serum lipidome of these 329 patients was profiled and analyzed to identify lipid species associated with AAA presence. Univariate analyses revealed a highly significant difference in age between the patients with AAA and controls with PAD. To assess whether age was the driving factor in observed associations between serum lipids and AAA presence, we selected a subset of 89 patients with AAA and 98 controls with PAD with no difference in median age. Lipidomic data from patients within this subgroup were independently analyzed to verify previously observed associations between serum lipids and AAA presence.
Patients
All serum samples were obtained from patients undergoing assessment for vascular disease at The Townsville and Mater Hospitals, Queensland, Australia, as previously described. 13 This study was conducted with approval from the Human Research Ethics Committees at James Cook University, The Townsville Hospital and the Mater Misercordiae Hospital, Townsville. All participants provided informed written consent. AAA cases were recruited from patients undergoing computed tomographic angiography (CTA) to assess AAA morphometry as part of their clinical care. For inclusion, cases required an AAA diameter of >40 mm, no symptomatic PAD, and CTA measurement of AAA diameter within 12 months of providing a serum sample. Controls were patients with lower limb intermittent claudication requiring CTA for further assessment of their PAD with infrarenal aortic (IRA) diameters <30 mm measured on a CTA performed within 12 months of providing a serum sample.
Clinical Risk Factors and Medications
Characteristics collected for each patient included sex, age, history of hypertension, diabetes mellitus, coronary heart disease (CHD), and prescribed medications. Diabetes mellitus and hypertension were defined by a history of diagnosis or treatment of these conditions. Smoking status was defined as having ever or never smoked. CHD diagnosis was based on a history of angina, myocardial infarction, or coronary artery revascularization. Current prescriptions for aspirin, calcium channel blockers, β-blockers, angiotensin-converting enzyme inhibitors, angiotensin 2 receptor blockers, diabetes mellitus medication, and lipid-modifying drugs were noted. Height and weight were measured by a research nurse in accordance with guidelines of the International Society for the Advancement of Kinanthropometry. 14 Body mass index was calculated as the body mass in kilograms divided by the square of height in meters. Serum CRP concentration was measured using an enhanced turbidimetric assay. Briefly 2.5-μL serum was incubated with 110-μL antihuman CRP monoclonal antibody-coated latex particles (Roche, Australia). After incubating at 37°C for 7 minutes, sample turbidity was measured at 552 nm using the COBAS Integra 800 series platform (Roche, Australia). Very LDL-C (VLDL-C) concentrations were estimated by subtracting combined HDL-C and LDL-C concentrations from total cholesterol for each patient.
CTA Imaging Protocol and Measurement of IRA Diameter
IRA diameter was determined by CTA using a 16-slice multiscanner (Philips, North Ryde, NSW, Australia) as previously detailed. 15 The IRA was scouted to identify the site of maximum dilation using the CTA viewer function on the Philips Workstation. Maximal aortic diameter was measured using electronic callipers to the nearest millimeter.
Sample Preparation and Lipid Extraction
Venous blood was collected into serum tubes (Vaccutainer, Greiner, Australia) after an overnight fast. Coagulated blood was centrifuged (12 minutes at 4500g), serum was decanted, and stored at −80°C until analyzed. Serum lipids were extracted using validated approaches. 12 In brief, 200 μL of a 2:1 choloroform:methanol mix was added to 10-μL serum. The samples were vortexed for 10 minutes, incubated in an ultrasonic waterbath at 40°C for 30 minutes, and rested for 20 minutes at ambient temperature. After centrifuging the samples (13 000g for 10 minutes), supernatants containing extracted lipids were dried under N 2 . The dried lipids were resuspended in 50-μL water-saturated butanol and 50 μL 10 mmol/L NH 4 COOH in MeOH. After centrifuging (4000g for 5 minutes), supernatants were transferred into HPLC glass vials with 0.2-mL microinserts and Teflon insert caps for liquid chromatography tandem MS (LC-MS/MS).
Lipid Analysis by LC-MS/MS
LC-MS/MS was conducted as previously described. 12 Briefly, online LC-MS/MS was performed using a Zorbax C18, 1.8 μm, 50×2.1 mm column connected to the ionization source of an API4000 QTRAP mass spectrometer (Applied Biosystems). Liquid chromatography was performed, at a flow rate of 300uL/min, using the following gradient conditions: 0% to 100% buffer B over 8.0 minutes, 2.5 minutes at 100% B, a return to 0% B >0.5 minutes, then 3.0 minutes at 0% B before the next injection. Diacylglycerols and triacylglycerols were separated using the same solvent system with an isocratic flow (100 μL/min) of 85% B. Solvents A and B consisted of tetrahydrofuran:methanol:water (30:20:50 and 75:20:5, respectively), both containing 10 mmol/L NH 4 COOH. Measurement of individual lipid species was performed using scheduled multiple-reaction monitoring in positive ion mode. Lipid measures were calculated by relating the peak area of each species to the peak area of the corresponding internal standard. Cholesterol ester species were corrected for response factors determined for each species. Total measured lipids of each class were calculated by summing the individual lipid species.
Serum Sphingosine-1-Phosphate Analysis
Serum sphingosine-1-phosphate (S1P) was measured via ELISA using the manufacturer's protocols (Antibodies-online.com).
Statistical Analysis
Median and interquartile range were used to represent continuous data, which was compared with the Mann-Whitney U test. Nominal data were presented as numbers and percentages and compared using Fisher exact test (2 sided P values reported). Binary logistic regression was used to determine the association of lipid species with AAA adjusting for covariates, showing significant differences between groups identified through univariate analyses. Thus, the lipidomic analysis was adjusted to account for age, diabetes mellitus, CHD, serum concentrations of CRP and creatinine, and the use of β-blockers and metformin. The same covariates, excluding age, were adjusted for in analyses conducted in the age-matched patients with AAA and controls with PAD. To limit the false discovery rate in logistic regression analyses of lipidomic data, P values were corrected using the Benjamini-Hochberg approach; a corrected P value <0.05 was considered to be statistically significant.
Significant differences in serum HDL-C concentration were observed between patient groups. This was not adjusted for since HDL-C is highly correlated with the serum concentration of individual lipid species concentration, and the current study is not sufficiently powered to identify HDL-independent associations of lipid species with AAA presence.
Approaches in machine learning were used to train and test cross-validated classification models that stratify AAA from controls with PAD. The classification models were based on regularized support vector machines with a polynomial kernel of order 2 coupled with ReliefF feature selection. 16, 17 We elected to apply machine learning-based approaches for the development of classification models because they are well suited to scenarios where the number of features exceeds the number of subjects. In the current study, the number of lipid species and risk factors assessed exceeds the number of subjects; therefore, a machine learning approach was considered appropriate. By applying feature selection approaches, such as relief, to optimize the selection of features included in the classification model, we were able to derive a classification model without having to assess all possible exhaustive combinations of features making this task computationally efficient and tractable as previously demonstrated. 12 The models were trained and tested within a 3-fold stratified cross-validation framework (200 repeats). The features available for incorporation into the model included clinical risk factors and 332 individual lipid species. The order of feature incorporation for training the classifier is based on the feature ranks assigned by the ReliefF feature selection algorithm computed on the training set of samples. 16 Classifier performance was assessed by the area under the receiver operator characteristic curve achieved for up to the first 20 features incorporated into the classifier. Three-fold cross-validation was repeated 200× and the mean and 95% confidence interval for the area under the receiver operator characteristic curve were calculated.
Results
Patient Selection
Sera from 329 participants (161 patients with AAA and 168 controls with PAD) were included in this analysis. The clinical characteristics of these participants are shown in Table 1 . Patients with AAA were older, had greater prevalence of CHD, and were less likely to have diabetes mellitus than controls with PAD. Serum concentrations of CRP and creatinine were significantly higher in the patients with AAA. Median serum HDL-C concentration was lower in patients with AAA when compared with controls with PAD. Medication use was similar between the groups although patients with AAA were more likely to be prescribed β-blockers, whereas a higher prevalence of metformin use was noted for controls with PAD. Consistent with selection criteria, median IRA diameter was significantly larger in the patients with AAA when compared with the control group.
Serum Lipid Profiling
The 329 serum lipid samples were randomized, and LC-MS/ MS was conducted in a blinded manner. Twenty-five quality control serum samples were placed evenly throughout the run to assess analytic precision. On the basis of the quality control samples the median coefficient of variation for lipids measured in this study was 10.4%. After excluding lipids showing >30% variation between quality control samples, comparative data were generated for 332 lipid species across 25 functional classes and subclasses. Initial comparisons demonstrated that relative levels of the majority of detected lipids were similar in patients with AAA and controls with PAD at both the species and functional class levels. Multivariate regression analyses adjusted for potential confounding factors (age, diabetes mellitus, metformin use, and serum CRP and creatinine concentrations) revealed tentative associations of total serum phosphatidylglycerol, diacylglycerol, and triacylglycerol with AAA (uncorrected P<0.05) when compared with controls with PAD although significance was lost after correcting for multiple comparisons ( Table I in the Data Supplement). Serum levels of 3 diacylglycerol and 7 triacylglycerol species were positively associated with AAA (Benjamini-Hochberg corrected P<0.05; Table 2 ). Serum lipids from other classes showed no association with AAA after adjusting for other risk factors ( Table I in the Data Supplement). Examination of the chemical structure of AAA-associated diacylglycerols and triacylglycerols species suggested that linoleic acid (18:2)-containing species were more closely related to AAA presence than lipids containing other fatty acid residues. Sixty percent of 18:2 containing diacylglycerols and 50% of 18:2 containing triacylglycerols detected by LC-MS/MS were positively associated with AAA presence after adjusting for other risk factors. Collectively, 18:2 residues were present within all AAA-associated lipids.
Subanalysis in Age-Matched Groups
Lipidomic data from a subgroup of age-matched patients with AAA and controls with PAD (n=89 and 98, respectively) were reanalyzed statistically to confirm that the observed associations of lipid species with AAA presence were not driven by the age imbalance in the initial cohort. The clinical characteristics of the 187 patients in this subanalysis are shown in Table  II in the Data Supplement. Significant differences in the prevalence of diabetes mellitus and CHD, serum concentrations of creatinine and CRP, and prescriptions for β-blockers and metformin were observed between the groups. These factors were included as covariates in regression analyses for this patient subset. Logistic regression analyses (adjusted for diabetes mellitus, CHD, serum concentrations of creatinine and CRP, and the use of metformin and β-blockers) confirmed significant positive associations between all 10 lipids identified in the initial analysis and AAA presence (Benjamini-Hochberg corrected P<0.05; Table 3 ; Table III in the Data Supplement). Two additional diacylglycerol and a further 8 triacylglycerol species were positively associated with AAA presence in this subanalysis (Data Supplement Table III ). Linoleic acid residues were observed in 71.4% of the AAA-associated lipids. Spearman ρ analyses demonstrated positive correlations All analyses are adjusted for age, diabetes mellitus, coronary heart disease, serum concentrations of C-reactive protein and creatinine, and the use of metformin and β-blockers. AAA indicates abdominal aortic aneurysm; CI, confidence interval; DG, diacylglycerols; PAD, peripheral artery disease; and TG, triacylglycerol.
*Odds ratio for an increase in serum concentration of 1 interquartile range. †Benjamini-Hochberg corrected P values (q values) generated from regression analyses. ‡Approximate difference in concentration between 25th and 75th percentiles (calculated via mass spectrometry).
between circulating levels of AAA-associated lipids and serum VLDL-C concentrations and negative correlations with serum HDL-C concentrations (Spearman ρ correlation coefficients, 0.45-0.69 and −0.36 to −0.49, respectively; all P values <0.001). Weakly significant negative correlations of 2 triacylglycerol species (triacylglycerol 18:1/18:1/18:2 and triacylglycerol 18:2/18:2/18:2) and serum LDL-C concentrations were also noted ( Table 3 ).
Sphingosine-1-Phosphate Analysis
Serum S1P concentration was measured via ELISA in samples collected from the 187 participants of the age-matched subanalysis. Serum samples from 3 patients gave readings beyond the detectable range of the kit and were removed from further analysis leaving a final sample of 87 patients with AAA and 97 controls with PAD. A weak, but significant positive correlation between serum concentrations of S1P and HDL-C was observed for this patient subset (Spearman ρ correlation coefficient, 0.146; P=0.048 Table III. ). Binary logistic regression (adjusted for diabetes mellitus, CHD, serum concentrations of creatinine and CRP, and the use of metformin and β-blockers) indicated a significant negative relationship between serum S1P concentration and AAA presence ( Table 4 ). This analysis suggested that patients with serum S1P in the third tertile (>191.5 ng/L) were ≈68% less likely to have AAA than patients in the lowest tertile (<142.8 ng/L; odds ratio, 0.321; 95% confidence interval [CI], 0.139-0.745; P=0.008). Calculated odds ratios suggested that patients with serum S1P concentrations in the second tertile (142. .5 ng/L) were ≈47% less likely to have AAA when compared with patients in the first tertile although statistical significance could not be demonstrated.
Multivariate Models to Discriminate Patients With AAA From Controls With PAD
Support vector machine-based classification models incorporating a combination of serum lipids and cardiovascular risk factors or risk factors alone were constructed using lipidomic For nominal characteristics, patients are compared to those without the risk factor. CHD indicates coronary heart disease; CI, confidence interval; CRP, C-reactive protein; and S1P, sphingosine-1-phosphate.
*Patients with S1P concentrations in the second and third tertiles were compared with patients with serum S1P in the first tertile.
†Odds ratios refer to an increase in serum concentration of approximately 1 standard deviation. and clinical data from all 329 patients. Features for inclusion in the nonlipidomic model were selected from a panel of traditional risk factors for AAA (age, sex, body mass index, diabetes mellitus, smoking, hypertension, CHD, and serum concentrations of CRP, total cholesterol, triglycerides and HDL-C). The same cardiovascular risk factors plus all lipid species identified via LC-MS/MS were available for the combined model. Serum S1P concentration was not included because this was not measured in all patients. The most frequently incorporated features in the risk factor classification model included diabetes mellitus, CRP concentration, age, HDL-C concentration, hypertension, and triglycerides. The most frequently incorporated features in the combined model included diabetes mellitus, CRP concentration, age, HDL-C concentration, hypertension, and total cholesterol, as well as 4 AAA-associated lipid species (triacylglycerol 18:2/18:2/18:2, triacylglycerol 18:1/18:2/18:2, triacylglycerol 18:1/18:1/18:2, and diacylglycerol 18:2/18:2). Diabetes mellitus, CRP concentration, age, and HDL-C were the most highly ranked features in both models; however, the combined model ranked 2 lipidomic features more highly than total cholesterol concentration and did not include serum triglycerides in the 10 most frequently incorporated features ( Table 5 ) in cross-validation.
For each model, a receiver operator characteristic curve was generated, and the area under the curve (AUC) was computed for each incorporated feature (Figure) . For both models, the AUC increased as more features were included although the AUC of the combined model rose sharply on incorporation of lipid species. The peak AUC of the combined model was significantly higher than the model incorporating traditional risk factors alone (peak AUC, 0.760; 95% CI, 0.756-0.763 and 0.719; 95% CI, 0.716-0.723, respectively; final increase in AUC, 0.041; 95% CI, 0.038-0.044; net reclassification improvement, 4.5%; P<0.05). Inclusion of >8 features only marginally improved performance of the combined model, suggesting that the first 8 features of this model had the greatest predictive power. Similarly, the first 5 features of the risk factor model conferred the greatest improvement to model performance; inclusion of ≥6 risk factors did not markedly increase AUC. The AUC for the combined model incorporating the first 8 features remained significantly higher than a model comprising the first 5 clinical features further indicating that consideration of lipidomic features improves patient stratification (mean AUC, 0.752; 95% CI, 0.748-0.756 and 0.716; 95% CI, 0.712-0.719, respectively; mean difference in AUC between the models, 0.036; 95% CI, 0.033-0.039; net reclassification improvement, 6.1%; P<0.05). This was verified by secondary analyses using nested models, suggesting that the inclusion of lipidomic features with a panel of clinical risk factors Table 5 improves detection of patients with AAA (Table IV in the  Data Supplement) .
. Features Incorporated into Classification Models Comprising Traditional Risk Factors Alone or a Combination of Serum Lipidomic Features and Traditional Risk Factors
Discussion
To our knowledge, this is the first study to examine in detail the association of serum lipid species with AAA. This was achieved using LC-MS/MS to profile the serum lipidome of 329 patients, followed by a subanalysis to confirm observed associations between serum lipids and AAA presence in an age-matched subset of 89 patients with AAA and 98 controls with PAD. Previous studies assessing the association of lipids with AAA were limited to measuring conventional lipid parameters, including total cholesterol, LDL-C, HDL-C, and triglyceride concentrations. No robust associations of AAA and circulating triglycerides have been observed after correcting for traditional risk factors. 7, 8, 17 In keeping with these previous studies, we found that total serum triacylglycerol and diacylglycerol levels were not associated with AAA presence. However, we identified consistent associations of 7 triacylglycerol species and 3 diacylglycerol species with AAA after adjusting for potential confounders and correcting for multiple comparisons. Calculated odds ratios suggest that individuals with elevated serum concentrations of each lipid are 60% to 90% more likely to have AAA when assessing a heterogeneous population of patients with vascular disease ( Table 2) . We also examined the association of the HDL-borne lipid S1P with AAA. We recently reported that S1P upregulation may contribute to the protective effect mediated by fenofibrate against AAA formation in a mouse model. 18 In agreement with findings from mouse studies, serum S1P concentrations were lower in patients with AAA, and a statistically significant negative association between AAA presence and serum S1P was observed after adjusting for other risk factors. 18 The role of circulating lipids in AAA pathogenesis is unclear. Inflammation, vascular smooth muscle cell (VSMC) apoptosis, thrombosis, and enzymatic destruction of the aortic extracellular matrix seem critical in AAA development and progression. 1 Three serum diacylglycerols were positively associated with AAA in this study. The relevance of serum diacylglycerols to AAA has not been previously examined although increased diacylglycerol levels within vascular endothelial cells and VSMCs has been suggested to contribute to AAA pathogenesis. Diacylglycerols are activators of the protein kinase C (PKC) family. PKC expression is significantly higher in AAA biopsies when compared with that in nonaneurysmal tissues, with VSMCs seeming to be the primary producers of these enzymes. 19, 20 Emerging evidence suggests that enhanced activity of PKCδ may drive several processes linked to AAA progression. First, PKCδ positively regulates monocyte chemoattractant protein 1 production by VSMCs. 19 In vitro and in vivo data confirm that inhibition of PKCδ significantly reduces extracellular concentrations of monocyte chemoattractant protein-1, associated with a concomitant reduction in the recruitment of inflammatory cells. 19, 20 Second, diacylglycerol/PKCδ signaling regulates lipotoxicity-induced VSMC apoptosis in vitro, evidenced by significant increases in cell survival through inhibition of PCKδ activity in palmitate-stressed VSMCs. 21 Finally, PKCδ-deficient mice seem resistant to elastase, and calcium chloride induced AAA formation evidenced by significantly smaller aortic diameter, and reduced aortic inflammation and VSMC apoptosis when compared with wild type controls. 20 Under normal physiological conditions, diacylglycerol kinase phosphorylates diacylglycerol to generate phosphatidic acid, thereby reducing intracellular diacylglycerol levels. 22 Previous research demonstrates that diacylglycerol/ PKC signaling is inhibited by peroxisome proliferator activated receptor (PPAR)γ agonists because of increased diacylglycerol kinase activity. 22 Observations that PPARγ agonist administration reduces induction of AAA in rodents further supports a pathogenic role for diacylglycerol/PKC signaling in AAA. 18, 23 Currently, it is unclear whether increased serum diacylglycerol encourages intracellular diacylglycerol accumulation, and further work is required to assess the mechanistic relevance of the identified diacylglycerols in AAA pathogenesis.
We also identified significant associations of 7 triacylglycerols with AAA presence. Evidence suggests that increased circulating triacylglycerol may contribute to endothelial dysfunction through generation of reactive oxygen species in patients with diabetes mellitus 24 but do not directly participate in vascular damage in PAD. 25 Triacylglycerol modification is thought to increase cardiovascular risk in 2 ways. First, triacylglycerol catabolism releases free fatty acids and cholesterol-containing lipoprotein remnants, which accumulate within the vascular endothelium and circulating macrophages to form foam cells, precipitating atherosclerotic plaque formation. 25, 26 Second, HDL-bound cholesterol esters are continuously exchanged for VLDL-borne triacylglycerol species by cholesteryl ester transfer protein. Triacylglycerol incorporation increases the ability of hepatic lipase to remodel HDL particles, ultimately enhancing HDL clearance by the kidneys. [27] [28] [29] In the current study, HDL-C concentration was significantly lower in the patients with AAA in line with previous reports. 30 Moreover, our data revealed the AAA-associated lipids to be strongly positively correlated with VLDL-C concentration and significantly negatively correlated with HDL-C concentration. It is tempting to suggest that the triacylglycerols identified here may play a more prominent role in augmenting HDL depletion in patients with AAA than other triacylglycerol species although detailed analyses are required to explore this hypothesis. However, these findings must be interpreted with care. VLDL-C was calculated by subtracting HDL-C and LDL-C concentrations from the total cholesterol concentrations, and data on the concentration of intermediate density lipoproteincholesterol concentration were not available. The possibility that reported VLDL-C concentrations may also include intermediate density lipoprotein-cholesterol cannot be discounted and we cannot conclusively state that the AAA-associated lipids are carried solely in the VLDL fraction. Future lipidomic studies to characterize the serum VLDL specifically, intermediate density lipoprotein and HDL-C fractions in patients with AAA are required to address this uncertainty and may identify further circulating lipids with biomarker potential.
Interestingly, our data suggest that the majority of AAA-associated lipids contain linoleic acid, an abundant essential n-6 polyunsaturated fatty acid within Western diets. Increased consumption of n-6 polyunsaturated fatty acids has been traditionally purported to raise the risk of developing atherosclerotic disease by stimulating vascular inflammation and increasing circulating oxidized LDL concentration although this remains controversial. 31 Some studies have suggested that prolonged exposure of vascular cells to n-6 fatty acids downregulates PPARα expression. 32, 33 PPARα ligation has been shown to be protective against AAA formation in animal models. 23 It is unclear whether linoleic acid bound within diacylglycerol and triacylglycerol molecules or products of their catabolism are able to exert similar effects, and future work is required to explore the relevance of linoleic acid to AAA.
We also examined the potential diagnostic value of combining AAA-associated serum lipid species with conventional cardiovascular risk factors to detect AAA presence. Addition of 4 lipid species to a panel of recognized AAA risk factors improved the ability to discriminate patients with AAA from controls with PAD evidenced by a significant increase in the area under the receiver operator characteristic curve although the value remained modest. Lipidomic features identified in this study are, therefore, unlikely act as stand-alone diagnostic markers for AAA. Our data indicated that some lipid species were more reliable indicators of AAA presence than total cholesterol and triglycerides, evidenced by preferential inclusion in the combined model. It is possible that more discriminatory models may be generated by combining the lipids identified in this study with other circulating biomarkers although the clinical usefulness of such a model would need to be assessed.
There were several limitations to this study. First, the number of cases and controls available was limited and precluded an independent validation of findings. However, our sample size (n=329) was larger than previous metabolomic investigations of AAA which typically include <50 participants. 34, 35 Second, renal function varied between the experimental groups evidenced by highly significant differences in circulating creatinine concentrations. It is possible that this may have directly influenced circulating lipid concentrations, particularly more water-soluble species although this was adjusted for in our multivariate analyses. Third, the controls in the current study were patients with lower limb atherothrombosis. Patients with AAA frequently have concurrent atherosclerosis. The presence of atherosclerosis in both groups may have complicated detection of lipid species associated with AAA. 36 However, this approach also had several advantages. Both cases and controls had undergone CTA imaging, allowing accurate assessment of IRA diameter, which would not have been possible in healthy controls. Also the comparison of patients with AAA and atherothrombosis, rather than healthy controls, is particularly relevant to clinical practice. We have previously examined the plasma lipidome of patients with atherothrombosis and this was not the focus of the current study. 12 The AAA cases were recruited from hospital-referred patients, thus patients referred for assessment of vascular disease who did not have AAA after undergoing similar imaging were appropriate controls. We accept that the AAA-associated lipids identified in the current study may differ from those that would be identified in a study using cases and controls recruited through community screening for AAA. Community screening for AAA is not available in Australia. The population examined in the current study is most relevant to AAA identification in countries where AAA screening is not offered. Ultimately, a successful diagnostic tool would need to distinguish patients with AAA from those with other vascular disorders, such as PAD, accurately. On the basis of these considerations, we believe that our study design is representative of the hospital-based identification of AAA and, therefore, clinically relevant. 1 Finally, many patients in the current study were taking lipid-modifying medications that could not be ethically withdrawn and may have confounded our assessment. However, lipid-modifying medication use was similar between patient groups and was not considered an important confounder in this study.
In conclusion, this study is the first to use a lipidomic approach to identify individual lipid species associated with AAA presence. Three diacylglycerol and 7 triacylglycerol species containing 18:2 residues were consistently positively associated with AAA. When considered alongside traditional clinical risk factors, serum concentrations of AAA-associated lipid species improved the ability to discriminate patients with AAA from controls with PAD when compared with consideration of established cardiovascular risk factors alone. Further study of the relevance of these lipid species and associated lipoproteins to AAA pathogenesis is required.
